Navigation Links
New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy
Date:9/24/2008

ibits the rapid firing nerve cells that cause seizures, has been developed to address the need for a new anti-epileptic agent that offers a reduction in seizure frequency combined with a favourable tolerability profile. Zebinix(TM) is currently under review by the EMEA (European Medicines Agency) for the treatment of partial-onset seizures with or without secondary generalisation in combination with other anti-epileptic drugs. A US NDA (New Drug Application) is expected later in 2008 or early 2009.

About the trials

The three phase III, multi-centre, randomised, placebo controlled trials involved more than 1,000 patients from 23 countries. Patients had a history of at least four partial seizures per month despite treatment with up to three concomitant anti-epileptic drugs.(2,3,4)

During the trials, patients were randomised to eslicarbazepine acetate or placebo and after a 2-week titration period, were assessed over a 12 week maintenance period, with continued follow-up over a one year open-label period.(2,3,4,7)

Efficacy

Over the 12 week maintenance period, Zebinix(TM) 800mg and 1200mg reduced seizure frequency by over one third, and was significantly more effective than placebo. This significant decrease in seizure frequency was sustained over the one-year open label treatment period and was consistent regardless of baseline therapy..(2,3,4) Similar positive findings were observed in the responder rate (greater-than-or-equal-to 50% decrease in seizure frequency) for Zebinix(TM) 800mg and 1200mg that ranged between 32% and 43% across all three phase III trials. (2,3,4)

Tolerability

The safety profile of Zebinix(TM) was favourable. The majority of treatment related adverse events were mild or moderate in severity and after 6 weeks, no relevant differences in the incidence of adverse events were apparent between patients treated with eslicarbazepine acetate and patients treated with placebo. In patients treated with Zebi
'/>"/>

SOURCE BIAL
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma
2. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
3. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
4. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
5. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
6. Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First Real World, All Comers Clinical Study
7. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
8. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
9. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
10. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
11. Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) ... health care leaders and a new study analyzing the impact of ... is a nationwide coalition working to educate policy makers and the ... the Capitol was focused on how the Iowa ...
(Date:1/23/2015)... ORLANDO, Fla. and DUBLIN , ... of the agreement with KRS Global Biotechnology, Inc. for the ... will be compounded for shipment in the United ... 503B FDA approved Outsourcing Facility capable of compounding naltrexone tablets ...
(Date:1/23/2015)... Inc. (ICBU) has repositioned itself as a holding company with ... in the hydroponic, hemp and medical marijuana sectors. By acquiring ... sector, and recently partnering with the Chippewa Tribe Nation to ... iMD is committing to bring its vision to the market ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... Inc. (NYSE: PFE ) invites investors and the general public to view and ... EDT on Tuesday, August 3, 2010 . The purpose of the call is ... Performance Report, to be issued that morning. , , ... ) , , , ...
... June 29 Accuray Incorporated (Nasdaq: ARAY ), ... Peter Fine as a member of the company,s Board of Directors ... Yu who has resigned effective June 28, 2010 . , ... Fine currently serves as the president and chief ...
Cached Medicine Technology:Pfizer Invites Public to View and Listen to Webcast of August 3 Conference Call With Analysts 2Accuray Appoints Peter Fine to Board of Directors 2Accuray Appoints Peter Fine to Board of Directors 3Accuray Appoints Peter Fine to Board of Directors 4
(Date:1/22/2015)... a seasoned and trusted leader who consistently delivers trendy dresses ... it lead the wedding dress industry into the future. Today, ... the global market. , “The CEO of VogueQueen is uniquely ... continuing the goal of operational excellence and giving back to ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently ... View website of AngelWeddingDress.com to find more details. ... online for a bridal party. AngelWeddingDress offers a variety ... Its maternity wedding dresses are specially designed for 2015. ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
(Date:1/22/2015)... January 22, 2015 Joan Lunden, award-winning ... speaker at the upcoming 32nd Annual Miami Breast ... Physicians’ Education Resource®, LLC (PER®) , shares that “a ... gone undetected if she had not followed up her ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... , , , KANSAS ... Benefits, a national carrier of group life, disability and dental ... Life Insurance Company,s group insurance business, subject to approval by ... , "This agreement reflects our commitment to ...
... rates of thinking about and attempting suicide than the ... at risk for suicidal behavior, according to new University ... U.S.-born Asian-American women have contemplated suicide in their lifetime, ... The finding comes in a study published in ...
... , , ORLANDO, Fla., Aug. 17 ... for the second year in a row. Inc. 5000,s list is comprised ... revenue growth between 2005 through 2008. , , ... as we have moved up 724 positions on the Inc. 5000 list," ...
... , ST. PAUL, Minn., Aug. 17 ... like smoke and smog, as well as other air pollutants ... to experience shortness of breath, wheezing and coughing, and may ... AIRNow.gov(2), a government-developed index for reporting daily air quality, the ...
... a 1-millimeter nematode worm is providing valuable new clues into ... in new tissues after spreading throughout the body. ... years studying the mechanics of a single cell in the ... the anchor cell and one of its jobs is to ...
... an MP3 device -- just about every man, woman and child on ... of music, of the primal place it holds in the human imagination. ... of the soul -- a frill that has to go when school ... The study shows that musicians -- trained to hear sounds embedded in ...
Cached Medicine News:Health News:Assurant Employee Benefits to Reinsure Shenandoah Life Insurance Company's Group Benefits Business 2Health News:US-born Asian-American women more likely to think about, attempt suicide 2Health News:US-born Asian-American women more likely to think about, attempt suicide 3Health News:American Home Companions Makes Inc. 5000 List Again 2Health News:Bad Air Day Alert: Outdoor Air Pollutants at High Level 2Health News:Bad Air Day Alert: Outdoor Air Pollutants at High Level 3Health News:Cancer's break-in tools possibly identified at Duke 2Health News:Taking up music so you can hear 2Health News:Taking up music so you can hear 3
The Microny pacemakers are among the smallest devices in the world. The Microny II SR+ pacemaker is the world's smallest, single-chamber rate-responsive pulse generator. The Microny pacemakers featur...
... family of pacemakers features several ... truly automatic devices in today's ... unparalleled combination of automated features ... builds on the popular and ...
... family, which includes the world's ... with the most advanced pacemaker ... AF Suppression™ algorithm, the first ... algorithm designed to suppress atrial ...
... Affinity pacemaker family offers ... truly automatic devices. Featuring ... of advanced technologies ever ... pacemaker incorporates the exclusive ...
Medicine Products: